65th ASH Annual Meeting & Exposition: Post-Translational Underpinnings of Therapy Response and Resistance to Therapy

Symposia: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies Scientific Workshops

Room 7 (San Diego Convention Center)

Moderator:

and Daniel T. Starczynowski, PhD, University of Cincinnati

Disclosures:

Starczynowski: Sumitomo Pharma Oncology: Research Funding; Captor Therapeutics: Consultancy; Kurome Therapeutics: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Treeline Biosciences: Research Funding; Tolero Therapeutics: Research Funding; Kymera Therapeutics: Consultancy.

Moderator Introduction

Daniel T. Starczynowski, PhD

Cancer Center, University of Cincinnati, Cincinnati, OH

Targeting Immune/Inflammatory-Related Pathways in Myeloid Malignancies

Daniel T. Starczynowski, PhD

Cancer Center, University of Cincinnati, Cincinnati, OH

N/KRAS-Mutant Acute Myeloid Leukemia Stem Cells Originate from Committed Myelomonocytic Progenitors and Drive Clinical Resistance to Venetoclax

Eirini Papapetrou, MD, Phd, MD, PhD

Icahn School of Medicine at Mount Sinai, New York, NY

Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Li Du, PhD

Judy and Bernard Briskin Center for Multiple Myeloma Research, Beckman Research Institute City of Hope, Duarte, CA; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; Toni Stephenson Lymphoma Center, Beckman Research Institute City of Hope, Duarte, CA

Panel Discussion

See more of: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
See more of: Scientific Workshops

<< Previous Session | Next Session >>